ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för afimoxifene. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

13 träffar

Bibliografisk träff 2020-03-10

Shikonin and 4-hydroxytamoxifen synergistically inhibit the proliferation of breast cancer cells through activating apoptosis signaling pathway in vitro and in vivo.

Lin HY, Han HW, Wang YS, He DL, Sun WX, Feng L, Wen ZL, Yang MK, Lu GH, Wang XM, Qi JL, Yang YH.

Chin Med · research-article; journal article · DOI 10.1186/s13020-020-00305-1

Bibliografisk träff 2020-02-26

Development and validation of UPLC-MS/MS method for studying the pharmacokinetic interaction of dasabuvir and tamoxifen, 4-hydroxytamoxifen in Wistar rats.

Almomen A, Maher HM, Alzoman NZ, Shehata SM, Al-Taweel SM, Alanazi AA.

Sci Rep · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41598-020-60613-2

Bibliografisk träff 2019-09-13

Elevated Hexokinase II Expression Confers Acquired Resistance to 4-Hydroxytamoxifen in Breast Cancer Cells.

Liu X, Miao W, Huang M, Li L, Dai X, Wang Y.

Mol Cell Proteomics · research-article; journal article; research support, n.i.h., extramural · DOI 10.1074/mcp.ra119.001576

Bibliografisk träff 2019-06-10

Plasma endoxifen and 4-hydroxytamoxifen levels in CYP2D6(C100T) carrying breast cancer patients and association with serum cholesterol.

Chao TC, Pan WC, Tsai YF, Chou YC, Liu YR, Wang SF, Chen YJ, Souček P, Ueng YF.

Toxicol Appl Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.taap.2019.114619

Bibliografisk träff 2019-05-01

Review: Patient-controlled transdermal 4-hydroxytamoxifen (4-OHT) vs. oral tamoxifen: A systematic review and meta analysis.

Sundralingam U, Khan TM, Elendran S, Muniyandy S, Palanisamy UD.

Pak J Pharm Sci · meta-analysis; systematic review; journal article

Bibliografisk träff 2019-04-01

4-Hydroxytamoxifen enhances sensitivity of estrogen receptor α-positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion.

Wang G, Qin S, Zayas J, Ingle JN, Liu M, Weinshilboum RM, Shen K, Wang L.

Breast Cancer Res Treat · research-article; journal article · DOI 10.1007/s10549-019-05194-z

Bibliografisk träff 2016-11-24

Targeting Cancer with PCPA-Drug Conjugates: LSD1 Inhibition-Triggered Release of 4-Hydroxytamoxifen.

Ota Y, Itoh Y, Kaise A, Ohta K, Endo Y, Masuda M, Sowa Y, Sakai T, Suzuki T.

Angew Chem Int Ed Engl · research support, non-u.s. gov't; journal article · DOI 10.1002/anie.201608711

Bibliografisk träff 2015-09-09

Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status.

Zhong Q, Zhang C, Zhang Q, Miele L, Zheng S, Wang G.

BMC Cancer · research-article; journal article; research support, n.i.h., extramural · DOI 10.1186/s12885-015-1621-2

Bibliografisk träff 2012-03-03

Importance of highly selective LC-MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen.

Jager NG, Rosing H, Linn SC, Schellens JH, Beijnen JH.

Breast Cancer Res Treat · journal article; case-report · DOI 10.1007/s10549-012-2000-1

Bibliografisk träff 2009-12-16

4-Hydroxytamoxifen inhibits K(+) currents in mouse ventricular myocytes.

El Gebeily G, Fiset C.

Eur J Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ejphar.2009.12.006

Bibliografisk träff 2007-03-10

A phase II trial of Afimoxifene (4-hydroxytamoxifen gel) for cyclical mastalgia in premenopausal women.

Mansel R, Goyal A, Nestour EL, Masini-Etévé V, O'Connell K, Afimoxifene (4-OHT) Breast Pain Research Group.

Breast Cancer Res Treat · clinical trial, phase ii; multicenter study; randomized controlled trial; journal article · DOI 10.1007/s10549-007-9507-x

Bibliografisk träff 2004-05-24

Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.

Desta Z, Ward BA, Soukhova NV, Flockhart DA.

J Pharmacol Exp Ther · research support, u.s. gov't, p.h.s.; journal article · DOI 10.1124/jpet.104.065607

Bibliografisk träff 2002-10-01

4-Hydroxytamoxifen is a potent inhibitor of the mitochondrial permeability transition.

Cardoso CM, Almeida LM, Custódio JB.

Mitochondrion · journal article · DOI 10.1016/s1567-7249(02)00034-x